The treatment of pyoderma gangrenosum using etanercept

J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S128-34. doi: 10.1016/j.jaad.2005.10.058.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Arthritis, Rheumatoid / epidemiology
  • Comorbidity
  • Etanercept
  • Female
  • Humans
  • Immunoglobulin G / administration & dosage
  • Immunoglobulin G / therapeutic use*
  • Lupus Erythematosus, Cutaneous
  • Male
  • Middle Aged
  • Pyoderma Gangrenosum / blood
  • Pyoderma Gangrenosum / drug therapy*
  • Pyoderma Gangrenosum / epidemiology
  • Pyoderma Gangrenosum / physiopathology
  • Receptors, Tumor Necrosis Factor / administration & dosage
  • Receptors, Tumor Necrosis Factor / antagonists & inhibitors
  • Receptors, Tumor Necrosis Factor / therapeutic use*
  • Recurrence

Substances

  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Etanercept